Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
Lamotrigine as Treatment of Myotonia
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Grete Andersen, MD
- Target Recruit Count
- 27
- Registration Number
- NCT01939561
- Locations
- 🇩🇰
Copenhagen Neuromuscular Center, department of Neurology, Rigshospitalet, Copenhagen, Denmark
Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)
- Conditions
- Interventions
- First Posted Date
- 2013-07-03
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT01891890
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 62
- Registration Number
- NCT01888731
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Balanagar, Hyderabad, India
Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 62
- Registration Number
- NCT01888757
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Balanagar, Hyderabad, India
Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 36
- Registration Number
- NCT01888250
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Balanagar, Hyderabad, India
Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 32
- Registration Number
- NCT01888263
- Locations
- 🇮🇳
Bioserve Clinical Research Private Limited, Balanagar, Hyderabad, India
PET and MRI Brain Imaging of Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 76
- Registration Number
- NCT01880957
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- Tri-Service General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01864551
- Locations
- 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)
- Conditions
- Interventions
- First Posted Date
- 2012-11-27
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 54
- Registration Number
- NCT01733394
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Drake University, Des Moines, Iowa, United States
Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2019-10-21
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT01674010
- Locations
- 🇹🇷
Elan Investigational Site, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.